Article Information
History
- February 4, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.
Author Information
- Zachary A. Weishampel1,
- Janean Young2,
- Mark Fischl2,
- Robert J. Fischer1,
- Irene Owusu Donkor1,3,
- Jade C. Riopelle1,
- Jonathan E. Schulz1,
- Julia R. Port1,
- Taylor A. Saturday1,
- Neeltje van Doremalen1,
- Jody D. Berry2,
- Vincent J. Munster1,* and
- Claude Kwe Yinda1
- 1Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, MT 59840, USA
- 2OraSure Technologies Inc., Research and Development, Bethlehem, PA 18015, USA
- 3Noguchi Memorial Institute for Medical Research, Epidemiology Department, University of Ghana, Legon, GHAN
- ↵*Correspondence: vincent.munster{at}nih.gov
Posted February 04, 2022.
OraSure InteliSwab® Rapid Antigen Test performance with the SARS-CoV-2 Variants of Concern Alpha, Beta, Gamma, Delta, and Omicron
